New drug targets tough cancer mutation in early trial
Disease control
Recruiting now
This early-stage trial tests a new drug called QTX3034, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 250 participants will take …
Phase: PHASE1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC